KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZN) Net Income towards Common Stockholders (2016 - 2026)

Astrazeneca has reported Net Income towards Common Stockholders over the past 16 years, most recently at $3.1 billion for Q1 2026.

  • For Q1 2026, Net Income towards Common Stockholders fell 23.33% year-over-year to $3.1 billion; the TTM value through Mar 2026 reached $12.0 billion, up 18.61%, while the annual FY2025 figure was $10.2 billion, 45.34% up from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 was $3.1 billion at Astrazeneca, up from $2.8 billion in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $4.0 billion in Q1 2025 and troughed at -$372.0 million in Q2 2022.
  • A 5-year average of $2.0 billion and a median of $1.9 billion in 2024 define the central range for Net Income towards Common Stockholders.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 131.26% in 2022 and later skyrocketed 588.71% in 2023.
  • Year by year, Net Income towards Common Stockholders stood at $1.7 billion in 2022, then increased by 4.03% to $1.8 billion in 2023, then decreased by 15.78% to $1.5 billion in 2024, then soared by 84.67% to $2.8 billion in 2025, then rose by 11.19% to $3.1 billion in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for AZN at $3.1 billion in Q1 2026, $2.8 billion in Q4 2025, and $2.6 billion in Q3 2025.